AbbVie Ups The Ante For Upadacitinib At EULAR
With data showing the superiority of its JAK inhibitor over Humira, the US firm is looking beyond treating the symptoms of rheumatoid arthritis to achieving remission.
With data showing the superiority of its JAK inhibitor over Humira, the US firm is looking beyond treating the symptoms of rheumatoid arthritis to achieving remission.